November 14, 2011 - Timothy Gardner (past-president of the American Heart Association) and Frank Sellke (Chairman of the Council on Cardiovascular Surgery and Anesthesia of the American Heart Association) review Cytograft’s first in human clinical results HERE.
July 15, 2011 - Cytograft highlighted in cover story in Medical Device Daily, found HERE.
June 27, 2011 - Dr. McAllister presents Cytograft's allogeneic vascular graft at the American Heart Association's prestigious Emerging Science series. The presentation can be found HERE.
June 20, 2011 - Cytograft publishes an article in Endovascular Today
December 8, 2010 - Dr. Nicolas L'Heureux, Cytograft's Chief Scientific Officer, opens and chairs the session Tissue Engineering and Regenerative Medicine in the Clinic at the North American meeting of TERMIS in Orlando, Florida.
November 22, 2010 - Dr. L'Heureux, co-founder and CSO of Cytograft, is featured in the "Industry Spotlight" of the Biomedical Engineering Society.
PIPELINE

Cytograft maintains a focused product portfolio targeted at cell-based solutions to cardiovascular disease. The company's lead product has shown promising results in phase I/II clinical trials as reported in the Lancet.

Our follow-on products include the LifeGuard™ patch and the LifeJacket™ stent-graft. These products take advantage of Cytograft's expertise in Tissue Engineering by Self-Assembly (TESA) and biological based treatments. These follow-on technologies range from discovery stage to advanced pre-clinical research to support FIM (first in man).

The company is also developing a line of surgical devices to support percutaneous bypass and other minimally invasive surgical approaches.

link to tebv link to covered stent link to patch link to percutaneous bypass link to valve

Gant Chart - Development Stage